Becton Dickinson & Co.

Becton Dickinson & Co.

BDX

Market Cap$48.46B
Close$

Compare to Similar Companies

P/E RatioDividendsReturn on EquityPrice-to-SalesDebt-to-Equity
Becton Dickinson & Co.Becton Dickinson & Co.32.52.36%3%2.40.3

Earnings Call Q2 2025

May 1, 2025 - AI Summary

Q2 Results Underperformance: BD reported a revenue growth of 6%, or 0.9% organic growth, which was below expectations. The underperformance was primarily due to challenges in the Life Sciences segment, driven by a reduction in research funding and a slower-than-anticipated recovery in blood culture testing within Diagnostics.
Revised Organic Growth Guidance: The company has adjusted its full-year organic growth forecast down to 3% - 3.5%, citing significant macroeconomic challenges, particularly in research funding policies and ongoing issues in their China market, including volume-based procurement impacts.
Strong Margin Performance: Despite the revenue challenges, BD was able to exceed its adjusted EPS expectations with growth of 5.7% to $3.35. The adjusted gross margin improved to 54.9%, up 190 basis points year-over-year, indicating effective cost management and productivity improvements through their BD Excellence initiative.

Exclusive for Stockcircle Pro members

Sign upSign Up
$260.00

Target Price by Analysts

54.8% upsideBecton Dickinson Target Price DetailsTarget Price
$615.00

Current Fair Value

266.2% upside

Undervalued by 266.2% based on the discounted cash flow analysis.

Share Statistics

Market cap$48.46 Billion
Enterprise Value$66.33 Billion
Dividend Yield$3.98 (2.35809930086503%)
Earnings per Share$5.88
Beta0.38
Outstanding Shares288,411,000

Return

Return on Equity-
Return on Assets-
Return on Invested Capital-

Valuation & Multiples

P/E Ratio32.5
PEG11.21
Price to Sales2.43
Price to Book Ratio1.47
Enterprise Value to Revenue3.29
Enterprise Value to EBIT33.76
Enterprise Value to Net Income38
Total Debt to Enterprise0.28
Debt to Equity0.34

Revenue Sources

No data

Insider Trades

ESG Score

No data

About Becton, Dickinson And Co.

72,000 employees
CEO: Thomas Polen

BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of hea...